Lipocine (NASDAQ:LPCN) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Lipocine (NASDAQ:LPCN) in a research report report published on Thursday morning. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Separately, Alliance Global Partners began coverage on Lipocine in a research note on Tuesday, September 24th. They set a “buy” rating and a $10.00 price target for the company.

Lipocine Stock Performance

Shares of LPCN stock opened at $4.89 on Thursday. The firm has a market cap of $26.15 million, a price-to-earnings ratio of -6.43 and a beta of 1.23. Lipocine has a 52 week low of $3.02 and a 52 week high of $11.79. The firm’s 50-day simple moving average is $4.99 and its two-hundred day simple moving average is $5.12.

Lipocine (NASDAQ:LPCN) last posted its quarterly earnings results on Thursday, November 7th. The specialty pharmaceutical company reported ($0.44) EPS for the quarter. Analysts forecast that Lipocine will post -0.78 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Lipocine stock. Renaissance Technologies LLC lifted its stake in Lipocine Inc. (NASDAQ:LPCN) by 21.8% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 25,697 shares of the specialty pharmaceutical company’s stock after acquiring an additional 4,600 shares during the period. Renaissance Technologies LLC owned approximately 0.48% of Lipocine worth $212,000 at the end of the most recent reporting period. 9.11% of the stock is owned by institutional investors.

About Lipocine

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.